Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
10
|
pubmed:dateCreated |
1997-1-7
|
pubmed:abstractText |
2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) induces aberrant crypt foci (ACFs) as well as colon cancer in F344 male rats. Conditions allowing rapid development of ACFs over a short period were investigated. F344 male rats were fed 400 ppm of PhIP x HCl in a low-fat diet (LF) for 2 weeks and then given a PhIP-free, high-fat diet containing PRIMEX (HF-PR) or safflower oil, or PhIP-free LF for 4 or 12 weeks. Rats fed HF-PR for 4 weeks gave the highest number of ACFs/rat (3.3) and their size in terms of aberrant crypts/ACF (2.7) was much larger than that obtained with conventional continuous feeding of PhIP for 25 weeks in the CE-2 diet. Therefore, 2 weeks of dietary exposure to 400 ppm of PhIP x HCl, followed by HF-PR for 4 weeks, is a practical and convenient method for obtaining ACFs. This protocol should be useful for studies of the early phase of colon carcinogenesis.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
0910-5050
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
87
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1029-33
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:8957059-Animals,
pubmed-meshheading:8957059-Body Weight,
pubmed-meshheading:8957059-Carcinogens,
pubmed-meshheading:8957059-Colon,
pubmed-meshheading:8957059-Colonic Neoplasms,
pubmed-meshheading:8957059-Dietary Fats,
pubmed-meshheading:8957059-Imidazoles,
pubmed-meshheading:8957059-Male,
pubmed-meshheading:8957059-Precancerous Conditions,
pubmed-meshheading:8957059-Rats,
pubmed-meshheading:8957059-Rats, Inbred F344
|
pubmed:year |
1996
|
pubmed:articleTitle |
Efficient method for rapid induction of aberrant crypt foci in rats with 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine.
|
pubmed:affiliation |
Carcinogenesis Division, National Cancer Center Research Institute, Tokyo, Japan.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|